The MAPK/ERK/MEK pathway has been demonstrated to be linked to chemotherapy resistance in numerous malignant tumors [14, 15], and the MAPK pathway has been reported to be involved in the growth and drug resistance of thyroid cancer [16–18]. This evidence concerns the gene MAP2K7 and thyroid gland carcinoma.